NASDAQ:ROSG - Rosetta Genomics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Rosetta Genomics Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$0.43MA: $0.43▼$0.4352-Week Range N/AVolume169,599 shsAverage Volume81,512 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ROSG Previous Symbol CUSIPN/A CIK1362959 Webhttp://www.rosettagenomics.com/ Phone972-73-222-0700Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive ROSG News and Ratings via Email Sign-up to receive the latest news and ratings for ROSG and its competitors with MarketBeat's FREE daily newsletter. If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks. Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions What is Rosetta Genomics' stock symbol? Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG." How were Rosetta Genomics' earnings last quarter? Rosetta Genomics (NASDAQ:ROSG) posted its quarterly earnings results on Thursday, May, 19th. The medical research company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.02. The medical research company earned $2.60 million during the quarter, compared to analysts' expectations of $3.36 million. View Rosetta Genomics' Earnings History. Has Rosetta Genomics been receiving favorable news coverage? Media stories about ROSG stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Rosetta Genomics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Rosetta Genomics. Who are some of Rosetta Genomics' key competitors? Some companies that are related to Rosetta Genomics include 89bio (ETNB), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Capstone Therapeutics (CAPS), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Immune Therapeutics (IMUN), Mereo BioPharma Group (MREO) and Myrexis (MYRX). What other stocks do shareholders of Rosetta Genomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rosetta Genomics investors own include Agenus (AGEN), Bausch Health Companies (BHC), Endocyte (ECYT), NovaBay Pharmaceuticals (NBY), Intercept Pharmaceuticals (ICPT), BIOLASE (BIOL), Eyepoint Pharmaceuticals (EYPT), Amicus Therapeutics (FOLD), Sucampo Pharmaceuticals (SCMP) and AEterna Zentaris (AEZS). Who are Rosetta Genomics' key executives? Rosetta Genomics' management team includes the folowing people: Mr. Kenneth A. Berlin, Pres & CEO (Age 54)Mr. Ron Kalfus CPA, Chief Financial Officer (Age 44)Mr. Oded Biran Adv., Gen. Counsel and Sec. (Age 39)Dr. Eti Meiri Ph.D., VP of Research (Age 50)Ms. Ana C. Ward Esq., M.S.,M.B.A., Exec. VP of Legal and Corp. Devel. What is Rosetta Genomics' official website? The official website for Rosetta Genomics is http://www.rosettagenomics.com/. How can I contact Rosetta Genomics? Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected] MarketBeat Community Rating for Rosetta Genomics (NASDAQ ROSG)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 200 (Vote Outperform)Underperform Votes: 165 (Vote Underperform)Total Votes: 365MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe ROSG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ROSG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2020 by MarketBeat.com StaffFeatured Article: What are economic reports?